Metagenomi (NASDAQ:MGX – Get Free Report) and Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, valuation, dividends and risk.
Valuation and Earnings
This table compares Metagenomi and Esperion Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Metagenomi | $25.21 million | 2.24 | -$87.87 million | ($2.37) | -0.63 |
| Esperion Therapeutics | $403.14 million | 1.22 | -$22.68 million | ($0.17) | -11.24 |
Profitability
This table compares Metagenomi and Esperion Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Metagenomi | -348.54% | -47.14% | -33.82% |
| Esperion Therapeutics | -3.66% | N/A | -3.93% |
Analyst Ratings
This is a summary of current ratings and target prices for Metagenomi and Esperion Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Metagenomi | 1 | 0 | 3 | 1 | 2.80 |
| Esperion Therapeutics | 1 | 0 | 5 | 1 | 2.86 |
Metagenomi presently has a consensus price target of $10.00, suggesting a potential upside of 566.67%. Esperion Therapeutics has a consensus price target of $8.75, suggesting a potential upside of 358.12%. Given Metagenomi’s higher possible upside, analysts plainly believe Metagenomi is more favorable than Esperion Therapeutics.
Institutional and Insider Ownership
47.4% of Esperion Therapeutics shares are owned by institutional investors. 17.8% of Metagenomi shares are owned by insiders. Comparatively, 1.7% of Esperion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Risk and Volatility
Metagenomi has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.
Summary
Esperion Therapeutics beats Metagenomi on 10 of the 14 factors compared between the two stocks.
About Metagenomi
Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
About Esperion Therapeutics
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company’s products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Receive News & Ratings for Metagenomi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metagenomi and related companies with MarketBeat.com's FREE daily email newsletter.
